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The DNMT3A R882H mutation 
does not cause dominant negative 
effects in purified mixed DNMT3A/
R882H complexes
Max Emperle1, Michael Dukatz1, Stefan Kunert1, Katharina Holzer1, Arumugam Rajavelu1,2, 
Renata Z. Jurkowska1,3 & Albert Jeltsch  1
The DNA methyltransferase DNMT3A R882H mutation is observed in 25% of all AML patients. DNMT3A 
is active as tetramer and the R882H mutation is located in one of the subunit/subunit interfaces. 
Previous work has reported that formation of mixed wildtype/R882H complexes leads to a strong loss 
of catalytic activity observed in in vitro DNA methylation assays (Russler-Germain et al., 2014, Cancer 
Cell 25:442–454). To investigate this effect further, we have prepared mixed wildtype/R882H DNMT3A 
complexes by incubation of individually purified subunits of the DNMT3A catalytic domain and full-
length DNMT3A2. In addition, we have used a double affinity tag approach and specifically purified 
mixed catalytic domain complexes formed after co-expression of R882H and wildtype subunits in  
E. coli cells. Afterwards, we determined the catalytic activity of the mixed complexes and compared 
it to that of purified complexes only consisting of one subunit type. In both settings, the expected 
catalytic activities of mixed R882H/wildtype complexes were observed demonstrating an absence of 
a dominant negative effect of the R882H mutation in purified DNMT3A enzymes. This result suggests 
that heterocomplex formation of DNMT3A and R882H is unlikely to cause dominant negative effects  
in human cells as well. The limitations of this conclusion and its implications are discussed.
Epigenetic regulation conveys heritable alterations in gene expression that are not caused by changes in the pri-
mary DNA sequence1. There are several types of epigenetic mechanisms, including methylation and hydroxym-
ethylation of cytosine residues in DNA (mostly in a CpG context), post-translational modifications of histone 
proteins and non-coding RNAs. DNA methylation is directly involved in many cellular processes by regulating 
genome stability, repression of repeat sequences, imprinting and cellular differentiation2,3. DNA methylation is 
introduced by enzymes called DNA methyltransferases (DNMT1, DNMT3A and DNMT3B)4,5 and removed 
with the help of TET methylcytosine dioxygenases6. Collectively, DNA methylation and demethylation repre-
sent critical mechanisms for cellular transformation and maintenance of cancerous cell programs7–9. In recent 
years, the rapid development of novel DNA sequencing techniques has revealed several genes that frequently 
contain somatic mutations in tumor tissues including DNA methylation regulators such as DNMTs and TETs9,10. 
Mutations in the DNMT3A DNA methyltransferase were reported for the first time in 2010, when it was found 
that a high frequency of missense mutations in DNMT3A occurs in AML11,12. This finding was later validated and 
further developed by several other groups reporting that about 25% of AML patients contain DNMT3A muta-
tions (reviews13,14). Later, recurrent DNMT3A mutations have been identified in other types of cancers, including 
myelodysplastic syndrome (MDS) and T-cell lymphomas (reviews13,14). DNMT3A mutations in AML usually 
occur heterozygously and they show a strong enrichment of missense mutations, in particular at arginine 882 in 
the catalytic C-terminal domain of DNMT3A, which is most often altered to histidine.
The structure of the C-terminal domain of DNMT3A (DNMT3AC) in complex with the C-terminal domain 
of its stimulator DNMT3L forms a linear heterotetramer consisting of two DNMT3L subunits (at the edges of the 
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tetramer) and two DNMT3A molecules (in the center)15,16 (Fig. 1). The DNMT3A/3 L interface is called FF inter-
face but it is also used for DNMT3A/3 A interaction in the absence of DNMT3L17,18. This hydrophobic interface 
is stable, allowing the co-purification of DNMT3A/3 L complexes15. The inner DNMT3A/3 A interface is called 
RD interface. It is a polar interface that mediates a reversible oligomerization of DNMT3A dimers (formed via 
the FF-interface) into a mixture of dimers, tetramers and higher aggregates depending on the buffer conditions 
and enzyme concentrations17–19. The RD interface also forms the DNA binding site of the DNMT3A complex15,17 
indicating that a tetramer is the smallest complex, which can be catalytically active.
The R882H mutation is located in the center of the RD interface suggesting potential effects on multimeri-
zation of DNMT3A and/or DNA interaction (Fig. 1). Different studies have determined the catalytic activity of 
the purified R882H mutant and observed 30–70% residual activity of the mutant enzyme (Table 1)12,20–23. Later, 
studies reported that the R882H mutation exhibits a dominant negative effect in cells and in vitro. Kim et al. 
(2013) showed that the exogenously expressed murine R878H mutant (corresponding to human R882H) inter-
acts with the wildtype enzyme, but it was less efficiently methylating major satellite repeats in mouse ES cells24. 
Russler-Germain et al. (2014) described that purified mixed enzyme preparations obtained after co-expression of 
wildtype and R882H in mammalian cells showed only 12% of residual activity in kinetic enzyme activity assays 
carried out in vitro. This observation led them to the conclusion that the R882H mutant has a dominant negative 
effect at the biochemical level and the formation of mixed complexes of wildtype and R882H subunits strongly 
reduces the activity of the mutant and wildtype DNMT3A subunits22.
Results
We were aiming here to investigate the mechanistic details of the dominant negative effect of the R882H mutation 
in mixed wildtype/R882H complexes22. We initially used the catalytic domain of DNMT3AC, because it can be 
purified with different affinity tags (see below) in good yields and sufficient quantities for the planned biochemical 
work15,17. DNMT3AC is enzymatically active25 and reproduces the stimulation by DNMT3L seen with full length 
enzymes26 indicating that it is a suitable model system to study multimerization and activity of DNMT3A. To 
start our work, we have prepared the R882H mutant in the context of His-tagged DNMT3AC and purified the 
proteins after recombinant expression in E. coli. In vitro methylation experiments using identical concentrations 
of DNMT3AC wildtype and R882H showed that the R882H mutant has a residual activity of approximately 65% 
with a 30 mer DNA substrate (Fig. 2A,C) that has been used as standard substrate in many of our previous pub-
lications17,18,25,27,28. This reduction in activity of R882H is comparable to results reported by most other groups 
(Table 1) in particular when considering that the relative activity of R882H is strongly dependent on the CpG site 
sequence context of the methylation substrate23.
Figure 1. Position of the R882H mutation in the structure of the DNMT3A/DNMT3L C-terminal domain 
heterotetramer with bound DNA (green)16. The DNMT3L C-terminal domains are colored dark and light red, 
the DNMT3A C-terminal domains are dark and light blue. AdoMet is shown in yellow and the positions of the 
Cα atoms of R882 in both DNMT3A subunits are indicated by orange balls. The regions of the DNMTR3A/3A 
RD interface and DNMT3A/3L FF interface are annotated in black.
Rel. activity of R882H Reference
44% Yamashita et al., Fig. 312
68% Yan et al., Fig. 2A (in presence of DNMT3L)20
54% Holtz-Schietinger et al., Table 321
29% Russler-Germain et al., Fig. 6C22
62% Emperle et al., Fig. 1A, 509mer DNA substrate23
65% This study
Table 1. Compilation of catalytic activities of DNMT3A R882H reported in different studies.
www.nature.com/scientificreports/
3ScIenTIfIc REPORts |  (2018) 8:13242  | DOI:10.1038/s41598-018-31635-8
Formation of wildtype/R882H complexes by mixing of purified subunits does not reduce the 
catalytic activity. To prepare for the kinetic analyses, we isolated the His-tagged wildtype and R882H pro-
teins separately and confirmed that under our assay condition and with the used 30mer oligonucleotide substrate 
enzyme activity is linearly related to the enzyme concentration, both for wildtype DNMT3AC and for R882H 
(Fig. 3A). This finding is in agreement with our previous studies with wildtype DNMT3AC28. To investigate the 
dominant negative effect of the R882H mutation in mixed wildtype/R882H complexes, the purified wildtype and 
R882H proteins were mixed and incubated together for 30 min to allow for subunit exchange. In parallel, each 
protein preparation was separately pre-incubated under the same conditions. Afterwards, we measured the cat-
alytic activities of all samples and compared the activity of the mixed sample with the activities of the individual 
subunits pre-incubated alone. However, we did not observe any difference between the activities of the mixed 
complexes when compared to the sum of the activities of the individual enzymes after equal treatment (Fig. 3B).
To confirm subunit exchange of the separately purified DNMT3AC wildtype and R882H subunits during the 
pre-incubation phase, wildtype DNMT3AC and R882H were cloned with His- and MBP-tags. All four proteins 
were purified by His- or MBP-affinity chromatography and the activity of the purified enzymes was determined. 
With MBP-tag, we observed approximately 65% residual activity of R882H (Fig. 2B,C), which is in agreement 
with the previous results obtained with His-tag purified enzyme. Moreover, we observed that MBP-tagged wild-
type DNMT3AC and R882H both showed about 40% reduction in activity when compared with the correspond-
ing His-tagged versions (Fig. 2D). Afterwards, Alpha-screen assays were conducted to investigate the subunit 
exchange of purified His- or MBP-tagged homomultimers (Fig. 3C). His-tagged wildtype DNMT3AC or R882H 
mutant were bound to Nickel chelate Alpha donor beads and MBP-tagged wildtype DNMT3AC to Anti-MBP 
acceptor beads. Both samples were mixed and incubated at ambient temperature and the Alpha signal deter-
mined for up to 45 min. Complex formation between the differently tagged subunits (presumably via the less 
stable RD interface) leads to a close approximation of the attached beads causing the emission of a detectable 
light signal. After mixing of His- and MBT-tagged wildtype DNMT3A, we indeed observed a clear increase in the 
Alpha-signal (Fig. 3C). After mixing of His-wildtype and MBP-R882H very similar kinetics of subunit exchange 
were observed. Fitting of the kinetics to an exponential curve revealed half-lives of 7–10 min in each case.
To confirm the conclusion of the Alpha-screen assays, that mixed complexes were obtained during the 
pre-incubation of separately purified enzyme preparations, we purified MBP-tagged wildtype DNMT3AC and 
pre-incubated it with purified His-tagged wildtype DNMT3AC or R882H. Afterwards, the protein complexes were 
purified over Ni-NTA beads (Fig. 3D). No MBP-tagged DNTM3AC was recovered in the absence of His-tagged 
proteins, showing the lack of unspecific interaction with the beads. In contrast, after pre-incubation with one 
of the His-tagged DNMT3AC proteins, similar amounts of MBP-tagged DNMT3AC were co-purified over the 
Ni-NTA beads indicating that mixed wildtype MBP-DNMT3AC were formed by wildtype His-DNMT3AC and 
His-R882H with comparable efficiencies.
All these data indicate that subunit exchange occurs during the pre-incubation phase of the enzyme activ-
ity assays described above. Based on the finding that pre-incubation of purified homomultimeric wildtype and 
R882H subunits did not lead to changes in activity although mixed wildtype/R882H complexes were formed, we 
conclude that a dominant negative effect of the R882H mutation could not be observed in this experiment.
Purified mixed wildtype/R882H complexes do not show dominant negative effects of the 
R882H mutation. To further investigate the activity of wildtype/R882H complexes, we directly purified 
mixed complexes by applying a double tag purification strategy29. To this end, different DNMT3A subunits were 
co-expressed with His- and MBP-tags and two successive steps of His- and MBP-affinity chromatography were 
applied, allowing the purification of heterotypic complexes containing subunits with both tags. To establish this 
protocol, we have used DNMT3AC mutations, which were shown to disrupt the FF (F732D) and RD inter-
face (R885 A)15,17. Note, that in the reference papers mouse DNMT3A numbering was used, such that the muta-
tions were designated as F728D and R881A. These experiments revealed that the co-purification of mixed His-/
MBP-tagged complexes with R885A mutation was possible, but purification of mixed complexes with the F732D 
mutation failed (Fig. 4). This result indicated that under the high salt conditions of this experiment mainly mixed 
Figure 2. Characterization of the activity of DNMT3AC R882H homomultimers. (A,B) Exemplary data 
showing catalytic activities of the purified His- and MBP-tagged DNMT3AC wildtype and R882H analyzed 
using a 30mer DNA substrate. (C) Summary of the effect of the R882H mutation on the catalytic activity of His- 
and MBP-tagged proteins. (D) Summary of the effect of the MBP-tag on the catalytic activity of DNMT3AC and 
R882H. Error bars in (C,D) indicate the SEM based on 5 independent experiments, in which DNMT3AC and 
R882H were expressed, purified and assayed in parallel.
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heterodimers formed via the FF-interface were purified. This finding is in agreement with the observation that 
high salt buffers disrupt the RD interface contact18. During and after dialysis these mixed heterodimers form 
different kinds of heterotetramers and higher complexes via their RD interface.
Next, mixed wildtype and R882H complexes were purified using both combinations of tags and subunits 
(Fig. 5A). As a control, wildtype DNMT3AC with His- and MBP-tags was co-expressed and purified using the 
same protocol. The subunit composition of the purified protein preparations was analyzed by SDS-gel electro-
phoresis (Fig. 5B) and the exact amounts of both subunits were determined from stained gel images. Using the 
experimentally measured activities of the His- and MBP-tagged wildtype and R882H subunits determined above, 
expected theoretical activities of the mixed complexes were calculated based on the subunit concentration in the 
purified enzyme samples. These calculated activities incorporate all the effects of the R882H mutation and of both 
tags on the overall activity, but they assume that the R882H and wildtype subunits do not influence each other. 
A dominant negative effect of R882H in mixed complexes would cause a drop in the observed activity of mixed 
wildtype/R882H complexes below the expected activity level. We experimentally determined the enzymatic activ-
ity of the mixed complex enzyme preparations, but found no difference to the expected values (Fig. 5C). We con-
clude that biochemically purified heterotypic R882H/wildtype DNMT3A complexes did not reveal evidence for 
a dominant negative effect of the mutant subunit on the wildtype subunit in in vitro DNA methylation kinetics.
Figure 3. Activity of R882H/wildtype DNMT3AC complexes obtained by mixing of independently purified 
subunits. (A) The catalytic activity of wildtype and R882H DNMT3AC is linearly dependent on the enzyme 
concentration under the assay conditions used here. (B) Activity of mixed DNMT3AC/R882H preparations 
after pre-incubation. The dark grey bar indicates the expected activity corresponding to the sum of the activities 
of the two subunit types, the light grey bar shows the observed activity. The error bar indicates the SEM based 
on 2 independent experiments. (C) Documentation of heterocomplex formation after pre-incubation of 
MBP- and His-tagged DNMT3AC subunits. In this assay, two subunit types were used with different tags (here 
His- and MBP-tag). Alpha acceptor and donor beads were bound to the tags and the samples were mixed. 
Formation of mixed complexes leads to an approximation of the two beads causing the emission of a light 
signal. The image shows Alpha-screen raw data observed after mixing of His and MBP-tagged DNMT3AC 
(blue curve) or MBP-DNMT3AC with His-R882H (orange curve). The signal observed after mixing of MBP 
with His-DNMT3AC (grey curve) illustrates the background. The experiment was carried out in triplicate and 
fitting of the averaged data revealed half-lives for the subunit exchange of 9.7 ± 2.2 min (average ± SEM) for the 
wildtype-MBP/wildtype-His combination and 7.4 ± 0.4 min for the wildtype-MBP/R882H-His combination. 
(D) Documentation of heterocomplex formation after pre-incubation of MBP-DNMT3AC (3AC-MBP) with 
His-DNMT3AC (3AC-His) or His-R882H (R882H-His). After the pre-incubation step, the proteins were 
purified over Ni-NTA beads. The specific co-purification of MBD-DNMT3AC indicated formation of mixed 
complexes with His-DNMT3AC and R882H-His.
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5ScIenTIfIc REPORts |  (2018) 8:13242  | DOI:10.1038/s41598-018-31635-8
Full length DNMT3A2 wildtype/R882H complexes do not show dominant negative effects of 
the R882H mutation. To study the effect of the R882H mutation in the context of full-length DNMT3A, 
we have used the His-tagged murine DNMT3A2 protein and introduced the R878H mutation (corresponding 
to R882H in human DNMT3A). DNMT3A2 is a naturally occurring isoform of DNMT3A, which is expressed 
from an internal start site and lacks 219 N-terminal amino acids30. Wildtype and R878H DNMT3A2 proteins 
were purified after recombinant expression in E. coli. In vitro methylation experiments using identical concen-
trations of both enzymes showed that the R878H mutant has a residual activity of approximately 61% with the 
30mer DNA substrate (Fig. 6A), which is very similar to the results obtained with the catalytic domain. To inves-
tigate potential dominant negative effects of the R878H mutation, we pre-incubated the wildtype and R878H 
DNMT3A2 proteins and determined the catalytic activity, which was then compared with the expected activity 
based on the contribution of the individual subunits pre-incubated under the same conditions. As shown in 
Fig. 6B, there was no detectable change in activity indicating the absence of dominant negative effects caused by 
the formation of mixed complexes in vitro.
Discussion
Despite the fact that the R882H mutation in the RD interface of DNMT3A is highly prevalent in AML, its path-
ogenic mechanism has not been finally clarified at the molecular level31. Most previous publications reported a 
moderately reduced activity of the mutant, but a general loss-of-function mechanism is not in agreement with 
the strong enrichment of this particular mutation, the general absence of insertions and deletions in the muta-
tional spectrum of DNMT3A and the heterozygous occurrence of the mutation accompanied by a wildtype 
DNMT3A allele. Russler-Germain et al. (2014) proposed a model in which the R882H mutation has a domi-
nant negative effect in mixed wildtype/R882H complexes, which was based on biochemical evidence discussed 
below22. To investigate this dominant negative effect experimentally in greater mechanistic details, we formed 
mixed wildtype/R882H complexes by pre-incubation of separately isolated wildtype and R882H DNMT3AC 
subunits. However, no dominant negative effect was observed. This result is in agreement with data reported by 
Russler-Germain et al. (2014)22. To explain the apparent lack of a dominant negative effect in this experimental 
setting, they argued that subunit exchange may not be possible after mixing of separately purified enzyme prepa-
rations. However, in our work we experimentally confirmed that mixed complexes are formed. This observation 
is also in agreement with previous biochemical work by several groups, which demonstrated that mixing of sepa-
rately purified DNMT3AC and DNMT3LC leads to subunit exchange and efficient formation of DNMT3AC/3LC 
complexes17–19,26,32–35. Similarly, we further show that mixing of mutant and wildtype full-length DNMT3A2 did 
not reveal dominant negative effects at the biochemical level.
We next have specifically purified mixed DNMT3A wildtype/R882H catalytic domain complexes and inves-
tigated their catalytic activities. To the best of our knowledge, our study for the first time reports the preparation 
of defined DNMT3A/R882H heterocomplexes which allows us to investigate potential dominant negative effects 
directly. However, similarly as in the experiments discussed in the last paragraph, no dominant negative effects 
were observed. This result is not in agreement with the reported results of Russler-Germain et al. (2014), but it 
is relevant to discuss some problems in the data interpretation of the previous publication. Russler-Germain et 
al. (2014) have determined the residual activity of R882H to be around 29% of wildtype DNMT3A, lower than 
results published by other labs (Table 1). Subsequently, they have co-expressed His-tagged wildtype DNMT3A 
and R882H and purified them together. They obtained a preparation containing about 50% of wildtype and 
R882H subunits, but observed an overall activity of only 12% and concluded that R882H has a dominant negative 
effect inhibiting the activity of wildtype subunits in mixed heterotetramers22. However, this biochemical result 
Figure 4. Characterization of the double-tag purification system of mixed His- and MBP-tagged DNMT3AC 
complexes. (A) Schematic representation of the purification of MBP- and His-tagged heteromultimeric 
DNMT3AC complexes by successive passage over MBP- and His- affinity columns. (B,C) Validation of the co-
purification procedure. While mixed wildtype/wildype and wildtype/R885A complexes can be purified with 
good yield, the F732D mutation in the FF interface prevents the purification of complexes. In contrast, the 
R885A mutation in the RD interface did not change the His/MBP stoichiometry of the co-purified complexes. 
These results indicate that mainly His/MBP FF-interface heterodimers are purified using this protocol. For the 
original images of panels B and C, cf. Suppl. Fig. 1.
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was surprising, because it is not compatible with a stochastic interface formation in which 25% wildtype/wildtype, 
50% wildtype/R882H and 25% R882H/R882H complexes should be formed and a residual activity of at least 
32.25% would have been expected (25% activity from the 25% wildtype homotypic complexes, which are fully 
active, plus 7.25% activity from the 25% R882H homotypic complexes) even if both subunits in mixed wildtype/
R882H complexes were assumed to be completely inactive. Based on this it is likely, that for technical reasons the 
mixed enzyme preparation had a reduced activity, which was not related to the presence of wildtype and R882H 
subunits.
Our data presented in this work shed strong doubts on the biochemical dominant negative model based on 
the formation of mixed heterocomplexes, suggesting that additional evidence would be needed to substantiate 
it. Although one cannot rule out that enzymes expressed in human cells may behave differently, the biochemi-
cal dominant negative effect model is currently lacking supportive evidence, because of the technical concerns 
regarding the work of Russler-Germain et al. (2014) and the lack of biochemical dominant negative effects in 
purified mixed DNMT3A/R882H complexes reported here. Several groups have observed that R882H leads to 
changes in the cellular DNA methylation in cancer cells, often hinting towards a dominant negative effect in 
cells22,24,36–38. However, a dominant negative behavior of R882H (or other DNMT3A mutants16) in cells may be 
explained by several other mechanisms unrelated to a direct inhibition of wildtype subunits in heterocomplexes. 
In addition, cellular effects may be related to changes in the flanking sequence of R882H recently observed by us, 
which modulate the effects of R882H on DNMT3A activity23. Resolving these issues will be of high relevance to 
understand the pathogenic mechanism of the R882H mutation in AML.
Methods
Site-directed mutagenesis, protein expression and purification. Mutagenesis was performed 
using the megaprimer site-directed mutagenesis method39 and confirmed by restriction marker analysis and 
DNA sequencing. The C-terminal domain of human DNMT3A (Q9Y6K1.4) (amino acids 612–912) and its 
R882H mutant were cloned into pET28 + (Novagen) creating an N-terminal His6-tag fusion and into pMAL p2X 
(New England BioLabs) creating an N-terminal MBP-tag fusion. His-tagged DNMT3AC and DNMT3A2 and 
their mutants were overexpressed in BL21 (DE3) Codon + RIL Escherichia coli cells (Stratagene) and purified as 
Figure 5. Purification and activity analysis of mixed R882H/wildtype DNMT3A complexes. (A) Schematic 
representation of the purification of mixed DNMT3AC/R882H complexes using a dual affinity approach. In 
this example, an MBP-wt/His-R882H complex is purified by successive passage over MBP- and His- affinity 
columns. (B) Example of purified His/MBP tagged mixed complexes. The image shows a Coomassie stained 
SDS-polyacrylamide gel. (C) Catalytic activities of purified His/MBP tagged heterotypic DNMT3AC complexes. 
On the left side, data for heterotypic His/MBP complexes containing two wildtype subunits are shown, on the 
right side, data for heterotypic wildtype/R882H complexes are displayed. The dark grey bars indicate expected 
activities corresponding to the sum of the activities of the two subunits, the light grey bars show the observed 
activities. Error bars indicate the SEM based on 3 independent experiments. For details of the analysis and the 
original image of panel B, cf. Suppl. Fig. 2.
www.nature.com/scientificreports/
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described28. Briefly, cells were grown in TB medium until an A600nm of 0.6 was reached and protein expression 
was induced for 12 h at 20 °C by addition of 0.5 mM isopropyl-1-thio-β-D-galactopyranoside. The proteins were 
purified at high micromolar concentrations using Ni–NTA agarose and stored in 20 mM HEPES pH 7.5, 200 mM 
KCl, 0.2 mM DTT, 1 mM EDTA and 10% glycerol at −80 °C. For purification of the MBP-tagged proteins, amyl-
ose resin matrix (New England Biolabs) was used and the proteins were eluted using 20 mM maltose and stored 
in 20 mM HEPES pH 7.5, 200 mM KCl, 0.2 mM DTT, 1 mM EDTA and 10% glycerol at −80 °C. Each protein was 
purified at least twice and the purity of the preparations was estimated to be >95% from Coomassie stained SDS 
gels. The concentrations of the proteins were determined by UV spectrophotometry and confirmed by densito-
metric analysis of Coomassie stained SDS–polyacrylamide gels.
Purification of mixed DNMT3A/R882H complexes. For purification of the mixed complexes consisting 
of His-DNMT3AC/MBP-DNMT3AC, His-DNMT3AC/MBP-DNMT3AC-R882H and His-DNMT3AC-R882H/
MBP-DNMT3AC, the corresponding subunits were co-overexpressed in BL21 (DE3) codon + RIL Eschericha 
coli cells (Stratagene). Cells were transformed with the pET28 + and pMAL vectors encoding for the corre-
sponding DNMT3A wildtype or mutant and cultivated in the presence of Kanamycin and Ampicillin to ensure 
the presence of both plasmids. Cells were grown in TB medium containing both antibiotics until an A600nm 
of 0.6 was reached and the protein expression was induced for 12 h at 20 °C by adding 0.5 mM isopropyl-1- 
thio-β-D-galactopyranoside. The mixed protein complexes were purified first over an amylose resin matrix (New 
England Biolabs) for binding MBP-tag containing protein complexes. The eluate was then used for a second 
purification step, using a nickel-NTA acid-agarose matrix for capturing all protein complexes which in addition 
to the MBP-tagged fusion proteins, contain His-tagged fusion proteins as well. The mixed complexes were stored 
in 20 mM HEPES/HCl pH 7.5, 200 mM KCl, 0.2 mM DTT, 1 mM EDTA, and 10% glycerol at −80 °C. The concen-
tration and purity of the different mixed complex preparations was determined by UV absorption at 280 nm and 
by densitometric analysis of Coomassie BB stained SDS-polyacrylamide gels using ImageJ.
Methyltransferase activity assay. The methyltransferase activity of DNMT3A was measured using a 
biotinylated double stranded 30-mer oligonucleotide (GAG AAG CTG GGA CTT CCG GGA GGA GAG TGC) 
containing a single CpG site as described28. Briefly, DNA methylation was measured by the incorporation of tri-
tiated methyl groups from radioactively labeled AdoMet (Perkin Elmer) into the biotinylated substrate, using an 
avidin–biotin methylation plate assay40. The methylation reactions were carried out in methylation buffer (20 mM 
HEPES pH 7.5, 1 mM EDTA, 50 mM KCl, 0.05 mg/ml bovine serum albumin) at 37 °C using 2 µM DNMT3AC 
wildtype or mutant enzyme, 1 µM DNA and the reaction was started by adding 0.76 µM AdoMet. The initial slope 
of the enzymatic reaction was determined by linear regression.
Subunit exchange experiments. To investigate the effect of the exchange of subunits on the catalytic 
activity of DNMT3AC, a mixture containing DNMT3AC-His and R882H-His (500 nM of each) was prepared and 
1 µM of the standard 30mer substrate was added in methylation buffer not containing AdoMet. As control, 1 µM 
of the separate proteins were used and treated identically. After 30 min of pre-incubation at ambient temperature, 
the methylation reactions were started by addition of 0.76 µM radioactively labeled AdoMet. Afterwards, the 
methylation reactions were processed as described before.
Subunit exchanged and formation of heterotypic complexes was studied by Alpha-assay using His-tagged 
and MBP-tagged proteins. For His-tagged proteins, nickel chelate donor beads (PerkinElmer) were used and for 
MBP-tagged proteins anti-MBP AlphaLISA acceptor beads (PerkinElmer). Each protein (250 nM) was separately 
incubated for 20 min at RT with 20 µg/ml of the corresponding beads to allow for binding. At the start point of 
the experiment, the corresponding samples were combined and Alpha-signal measurements were taken after 0, 
Figure 6. Effect of the RH mutation in the context of DNMT3A2. (A) Characterization of the activity of 
wildtype and mutant DNMT3A2 homomultimers. The error bar indicates the SEM based on 4 independent 
experiments. (B) Activity of mixed wildtype and mutant DNMT3A2 preparations after pre-incubation. The 
dark grey bar indicates the expected activity corresponding to the sum of the activities of the two subunit 
types, the light grey bar shows the observed activity. The error bar indicates the SEM based on 2 independent 
experiments.
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5, 10, 15, 30 and 45 min using an EnSpire Alpha Plate Reader (PerkinElmer). Signals obtained after incubation of 
the corresponding His-tagged DNMT3 proteins with untagged MBP or empty beads were used as control. Since 
it is known that the concentration of monomeric DNMT3 species is low17,19 the rate limiting step for subunit 
exchange is the dissociation of existing complexes. Therefore, the data were fitted by non-linear regression to a 
monomolecular decay function using the solver function of Microsoft Excel to determine the half-lives of subunit 
exchange.
Subunit exchanged and formation of heterotypic complexes was also studied by co-purification with Ni-NTA 
acid-agarose beads. For this, MBP-DNMT3AC was pre-incubated with His-DNMT3AC or His-R882H in incu-
bation buffer (25 mM Tris/HCl pH 7.5, 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-40, 200 µM PMSF) 
and the pre-incubated mixtures were bound to 100 µl Ni-NTA beads, washed 3 times with wash buffer (25 mM 
Tris/HCl pH 7.5, 300 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% NP-40, 200 µM PMSF) and afterwards eluted 
in 300 µl of wash buffer supplemented with 220 mM Imidazole. The eluted proteins were TCA precipitated and 
loaded on SDS polyacrylabmide gels stained with Coomassie BB. Identical reactions without His-tagged protein 
were carried out as controls.
Data Availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files).
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